MX2021003006A - Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne. - Google Patents

Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.

Info

Publication number
MX2021003006A
MX2021003006A MX2021003006A MX2021003006A MX2021003006A MX 2021003006 A MX2021003006 A MX 2021003006A MX 2021003006 A MX2021003006 A MX 2021003006A MX 2021003006 A MX2021003006 A MX 2021003006A MX 2021003006 A MX2021003006 A MX 2021003006A
Authority
MX
Mexico
Prior art keywords
acne
bacteriotherapy
treatment
proprionibacterium acnes
proprionibacterium
Prior art date
Application number
MX2021003006A
Other languages
English (en)
Spanish (es)
Inventor
Teruaki Nakatsuji
Richard L Gallo
Alan O O´Neill
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2021003006A publication Critical patent/MX2021003006A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
MX2021003006A 2018-09-13 2019-09-13 Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne. MX2021003006A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730999P 2018-09-13 2018-09-13
PCT/US2019/051156 WO2020056359A1 (en) 2018-09-13 2019-09-13 Bacteriotherapy against proprionibacterium acnes for the treatment of acne

Publications (1)

Publication Number Publication Date
MX2021003006A true MX2021003006A (es) 2021-05-27

Family

ID=69777906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003006A MX2021003006A (es) 2018-09-13 2019-09-13 Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.

Country Status (10)

Country Link
US (1) US20210283215A1 (enExample)
EP (1) EP3849573B1 (enExample)
JP (2) JP7624219B2 (enExample)
KR (1) KR20210102871A (enExample)
CN (1) CN113286602A (enExample)
AU (1) AU2019339515B2 (enExample)
BR (1) BR112021004538A2 (enExample)
CA (1) CA3112041A1 (enExample)
MX (1) MX2021003006A (enExample)
WO (1) WO2020056359A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234382A1 (en) * 2019-05-20 2020-11-26 Lactobio Aps Composition for treatment, alleviation or prophylaxis of acne
CN115261495B (zh) * 2021-04-30 2024-11-22 上海旺旺食品集团有限公司 一种检测金黄色葡萄球菌的方法、检测系统及其应用
CZ2021461A3 (cs) * 2021-09-30 2023-02-15 BiomServ s.r.o. Přípravky na ochranu mikrobiomu kůže a sliznic proti patogenním mikrobům a virům
CN114990237B (zh) * 2021-10-29 2024-11-26 成都中医药大学 一种检测金黄色葡萄球菌的引物、试剂盒和方法
CN115569229B (zh) * 2022-08-30 2023-12-22 中南大学湘雅三医院 搭载多种后生元成分的皮肤软组织保护材料及其制备方法
CN115852004B (zh) * 2023-02-07 2025-12-12 南京大学 一种表皮葡萄球菌的病原体特异性核酸基因及检测方法
CN116270368A (zh) * 2023-05-15 2023-06-23 天津悟空美容科技有限责任公司 一种抗痤疮化妆品及制备方法
CN118755644B (zh) * 2024-09-05 2025-02-11 山东福瑞达生物股份有限公司 一株头状葡萄球菌、一种菌剂及应用和一种头皮护理产品
CN119391608B (zh) * 2025-01-02 2025-10-28 中国疾病预防控制中心传染病预防控制所 表皮葡萄球菌共生菌cgmcc no.31064及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111913B2 (en) * 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
WO2015097061A1 (en) 2013-12-23 2015-07-02 Bruker Daltonik Gmbh Identification of methicillin resistant staphylococcus aureus (mrsa)
EP3903824A1 (en) 2014-01-10 2021-11-03 The Regents of The University of California Skin probiotic
MX2017014020A (es) * 2015-05-05 2018-08-14 Univ California Terapia antimicrobiana.
CN107794232B (zh) * 2016-08-31 2022-03-08 广州金羿噬菌体生物技术有限公司 拮抗痤疮丙酸杆菌和革兰氏阳性菌生长的链球菌及其代谢产物

Also Published As

Publication number Publication date
KR20210102871A (ko) 2021-08-20
JP2022501330A (ja) 2022-01-06
CA3112041A1 (en) 2020-03-19
EP3849573B1 (en) 2025-10-29
WO2020056359A1 (en) 2020-03-19
AU2019339515B2 (en) 2026-04-23
AU2019339515A1 (en) 2021-03-25
CN113286602A (zh) 2021-08-20
JP7624219B2 (ja) 2025-01-30
EP3849573A1 (en) 2021-07-21
JP2024112944A (ja) 2024-08-21
US20210283215A1 (en) 2021-09-16
BR112021004538A2 (pt) 2021-06-08
EP3849573C0 (en) 2025-10-29
EP3849573A4 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
EA201890218A1 (ru) Ретиноидные композиции для местного применения
CO2019006292A2 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
PH12020550474A1 (en) Topical pharmaceutical composition of adapalene and minocycline
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
EA201790398A1 (ru) Способы лечения заболевания печени
UY36032A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CL2017000866A1 (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos
PT3405215T (pt) Métodos para o tratamento da doença de danon e outros transtornos da autofagia
MX2018014083A (es) Composiciones nutritivas para la proteccion cardiaca en animales de compañia.
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
EP3849573C0 (en) Bacterial therapy against Propionibacterium acnes for the treatment of acne
MX2018003023A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
MX2021000363A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
EP4003299A4 (en) Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2018000274A (es) Bacterias oxidantes de amoniaco para el tratamiento del acne.
MX2021001435A (es) Tripeptidos y tratamiento de trastornos metabolicos, cardiovasculares e inflamatorios.
MX2022000845A (es) Compuestos inhibidores.
MX2018012230A (es) Métodos para tratar enfermedades oculares.
BR112021011368A2 (pt) Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos